✦ LIBER ✦

The Use of Valeriana officinalis (Valerian) in Improving Sleep in Patients Who Are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5)

✍ Scribed by Debra L. Barton; Pamela J. Atherton; Brent A. Bauer; Dennis F. Moore Jr; Bassam I. Mattar; Beth I. LaVasseur; Kendrith M. Rowland Jr; Robin T. Zon; Nguyet A. LeLindqwister; Gauri G. Nagargoje; Timothy I. Morgenthaler; Jeff A. Sloan; Charles L. Loprinzi

Book ID: 116893236
Publisher: Frontline Medical Communications, Inc.
Year: 2011
Tongue: English
Weight: 430 KB
Volume: 9
Category: Article
ISSN: 1544-6794
DOI: 10.1016/j.suponc.2010.12.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase III, double-blind, placebo-contr

A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer

✍ R. Pirker; J. Vansteenkiste; J. Gateley; P. Yates; A. Colowick; J. Musil 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 349 KB

Efficacy and safety of sublingual fentan

Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial

✍ Shimoyama, Naohito; Gomyo, Ikuo; Katakami, Nobuyuki; Okada, Masakuni; Yukitoshi, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 282 KB

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors : A randomized, Phase III, double-blind, placebo-controlled trial

✍ Lee S. Rosen; David Gordon; N. Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

Corrigendum to ‘A phase III, double-blin

Corrigendum to ‘A phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer’ Eur J Cancer 2001, 37, S264–S265. R. Pirker, J. Vansteenkiste, J. Gateley, P. Yates, A. Colowick, J. Musil

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB